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Abstract  
Objective: This study was conducted to assess pharmacists’ practices when counseling patients on their prescription medications, and 
their preferences for training. 
Methods: Five focus group discussions of community pharmacists (n=45, with seven to eleven participants in each group) were 
conducted in a major metropolitan city in the southern United States. Participants were recruited via email using a list of community 
pharmacists provided by the Texas State Board of Pharmacy.  All focus group discussions were structured using a moderator guide 
consisting of both discrete and open-ended questions. Qualitative analysis software was used to analyze the data with a thematic 
analysis approach.  
Results: The participants in this study had a high self-efficacy regarding their ability to counsel on both new and opioid prescriptions. 
Many pharmacists experienced the same barriers to counseling and agreed on the components of counseling. However, the themes 
that emerged showed that the participants exhibited only a partial understanding of the components of counseling. The themes that 
emerged in the thematic analysis were perceived confidence and discordant counseling practices, inadequate infrastructure, lack of 
comprehensive counseling, inconsistent use of the Prescription Drug Monitoring Program (PDMP), and pharmacists’ desired 
training/assistance.   
Conclusions: Community pharmacists are in a unique position to help combat the opioid crisis; however, there has been very little 
research on the pharmacist-patient interaction in this context. With policy changes, such as the PDMP mandate, going into effect 
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INTRODUCTION 
In the 1990s, pharmaceutical companies began to promote 
opioid medications as a safe method of treatment, with a 
low addiction profile, for chronic or persistent pain.
1
 As a 
result, opioid prescribing increased.
2
 While many people 
can benefit from the pain management these medications 
provide, the increase in prescriptions has increased rates of 
diversion, misuse, dependency, and opioid use disorder 
(OUD).
3,4
 In 2017, an estimated 1.7 million people within 
the United States suffered from an OUD.
5
  
The severity of the opioid crisis has gained the attention of 
federal agencies. The United States Department of Health 
and Human Services (HHS) declared the crisis to be a public 
health emergency and outlined a 5-point plan to combat 
it.
6
 The Agency for Healthcare Research and Quality (AHRQ) 
released a Special Emphasis Notice committing to the HHS 
mission to end the opioid crisis.
7
 
 When discussing interventions to ameliorate the opioid 
epidemic, community pharmacists are in a unique position 
to aid in efforts to increase prevention as well as improve 
access to effective treatment, recovery, and harm 
reduction strategies. Not only are they the gatekeepers to 
prescription medications with the ability to restrict access 
to controlled substances, they are also consistently ranked 
as one of the most trusted professionals.
8-10
 Additionally, 
pharmacists see their patients up to 10 times more than 
primary care physicians – making them the most accessible 
health care professional in the community.
11
 Their role 
extends beyond simply filling and dispensing prescription 
medications; they have a duty to provide counseling to 
patients on the medications they fill.
12,13
 Counseling plays 
an even more important role for patients receiving 
controlled substance prescriptions (CSP), as it is imperative 
to provide safe  usage, storage, and disposal information to 
prevent misuse and diversion.  
The Prescription Drug Monitoring Program (PDMP) is a tool 
intended to aid community pharmacists. It is an electronic 
database that provides a patient’s filling history of 
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controlled substances across different pharmacies 
regardless of payer.
14
 From March 1, 2020, Texas law will 
mandate that every pharmacist in the state should check 
the PDMP before dispensing a prescription for an opioid, 
benzodiazepine, barbiturate, or carisoprodol.
14
 Having 
access to a patient’s medication history of controlled 
substances gives the pharmacist more insight into the 
patient’s treatment, thereby guiding two clinical decisions – 
whether to fill and how best to counsel the patient. 
The majority of studies assessing the utilization of PDMPs 
has focused almost entirely on the quantitative utilization 
of the PDMP. For example, a study involving Indiana 
pharmacists found that pharmacists who regularly used the 
PDMP consistently were 3.3 times more likely to refuse to 
fill a CSP compared to those who did not use the PDMP at 
all.
15
 Both physicians and pharmacists have expressed the 
opinion that the PDMP is burdensome and may 
inappropriately reduce the number of opioids prescribed.
16
 
A recent study conducted in Kansas Medicaid patients 
attributed the utilization of the state PDMP to difficulty in 
obtaining a CSP in patients with chronic non-cancer pain.
17
 
There are additional studies that address this issue.  
Pharmacists in Indiana also indicate that the perception of 
a barrier will decrease PDMP utilization and pharmacists in 
Kansas attributed “internet access” as the primary reason 
for not using the PDMP.
18,19
 
Given the potential that pharmacists have in providing 
interventions in the pharmacy setting, it is necessary to 
understand the issue from their perspective. Research on 
pharmacists’ willingness to counsel patients with a CSP 
after reviewing the PDMP identified a total of 15 
behavioral, 14 normative, and 11 control beliefs.
20
 While 
pharmacists did acknowledge the benefit of counseling, 
they still cited patient confrontation as the biggest 
deterrent to engaging patients in the context of CSPs.
20
 
Other elicited beliefs extrapolated on the willingness of 
pharmacists to engage with patients and has provided 
much-needed insight into the pharmacist-patient 
interaction. However, there has been little research into 
the content of the interaction. Assessing and understanding 
pharmacists’ counseling practices will assist in identifying 
any barriers, reluctance, or gaps in counseling; and, in turn, 
developing necessary educational interventions to address 
these deficiencies.  Ultimately, this knowledge will help 
capitalize on the potential of community pharmacists in 
efforts to mitigate the opioid crisis.  
Therefore, the objective of this study was to assess 
pharmacists’ practices when counseling patients on their 
prescription medications, the barriers to counseling, and 
their preferences for training. 
 
METHODS 
Study design and setting 
This descriptive, qualitative study using focus group 
discussions was intended to assess pharmacists’ practices 
when counseling patients on their prescription 
medications, the barriers they face, and their preferences 
for training. The focus group discussions were held at an 
agency that specializes in qualitative research located in a 
major metropolitan city in the southern United States. 
Participants and recruitment 
The sample was generated via convenience sampling. 
Pharmacists in the area were identified using the list of 
actively licensed community pharmacists maintained by the 
Texas State Board of Pharmacy (TSBP). Recruitment was 
managed by the qualitative research group, who also 
moderated and transcribed the focus group discussions.  
While the inclusion criteria were limited to pharmacists 
currently working in a community pharmacy setting, care 
was taken to invite participants from a variety of retail 
settings (i.e., mass merchandiser, retail chain, and 
independent) to improve the generalizability of the results. 
Of those invited, a sample of 45 pharmacists was generated 
and divided into five different focus groups. Each focus 
group had between 7 to 12 participants and lasted 
between 90 and 120 minutes. Three focus groups were 
initially scheduled, but two more were added as new ideas 
were still being explored by the participants.  
 Prior to attending the focus groups, the participants were 
given information about the study and informed consent. 
To maintain the anonymity of the participants, minimal 
demographic information was collected, and the 
participants were asked to use their initials as their 
pseudonyms. Participants were reimbursed USD 250 for 
their time and effort.  The study was approved by the 
University of Houston Institutional Review Board. 
Data collection 
Two members of the research team created the moderator 
guide which did not change between individual focus 
groups (See Online appendix). The moderator guide 
consisted of four sections, each with a point of emphasis 
and a mix of discrete and open-ended questions. The initial 
sections addressed prescription medications in general 
while the latter narrowed the focus to opioid medications. 
The first section contained the moderator’s introduction, 
disclosures, and guidelines for the information collected, 
and each participant’s introduction. The next section 
focused on counseling on new prescriptions. Participants 
were first asked to estimate the percentage of new 
prescriptions they counsel on, followed by the reasons they 
counsel, barriers to counseling, and their comfort level (on 
a scale of one to five, with five being the greatest level of 
comfort) on counseling for new prescriptions. The 
participants were asked to respond according to their 
current situation. Participants were also asked to elaborate 
on the reasoning behind their comfort rating. 
The third section of questions narrowed the conversation 
to counseling on opioid medications. Similar to the 
previous section, it started with a discrete question asking 
participants to estimate the percentage of opioid 
prescriptions they counsel. It then delved into asking them 
to discuss their attitudes towards opioid medications when 
prescribed in conjunction with other controlled substances, 
barriers to counseling, and the components of counseling. 
If the participants did not bring up safe storage, disposal, 
and referral options, the moderator was instructed to ask 
about them specifically. The final section of the moderator 
guide focused on training preferences. It asked for 
information regarding the following: whether the 
pharmacists thought they required training, the content 
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the training should cover, and the method or modality 
through which the training should be offered.  
Data analysis 
Two research team members reviewed and initially coded 
the focus group transcripts. A thematic analysis approach 
was used to analyze the data. Thematic analysis is a 
qualitative descriptive method used to identify and analyze 
repeating patterns within a set of data.
21
 The research 
team followed the established six steps for thematic 
analysis: 
1. Data Familiarization: Each member read the five focus 
group transcripts independently without any a priori 
assumptions and took notes on initial observations.  
2. Generating Codes: The members met and discussed the 
important aspects and relevant reoccurring themes in 
the transcripts. Then, each member independently went 
through the transcripts and created their own codes. 
The two separate code lists were reconciled through 
discussion between the research team members with a 
faculty member serving as an arbitrator. This process 
resulted in the final list of codes, also referred to as the 
codebook.  
3. Searching for Themes: Once the codebook was 
generated, both members of the research team met to 
organize the codes into overarching themes.  
4. Reviewing Themes: Traditionally, this step would be 
used to reconcile any differing themes and generate a 
thematic map. In this study, the themes were discussed 
and compiled together, so there was no need for 
reconciliation. Additionally, the software used in this 
study, ATLAS.ti© V722, can generate semantic 
networks.  
5. Defining and Naming Themes: Once the themes were 
decided upon, the two members of the research team 
responsible for the coding and the arbitrating faculty 
member jointly reviewed and named the themes 
appropriately.  
6. Producing the Report: The final report consisted of the 
coded, merged, and reconciled five transcripts along 
with the codebook and themes. 
 
RESULTS  
In this study, five focus group discussions, totaling 45 
pharmacists, were held in May 2018. The majority of 
participants were female and had worked in community 
pharmacy for 10 years or longer (Table 1). All focus groups 
were structured by the same moderator guide. Through the 
thematic analysis process, five main themes emerged: 
perceived confidence and discordant counseling practices, 
Lack of comprehensive counseling, inadequate 
infrastructure, pharmacists’ desired training/assistance, 
and inconsistent use of the PDMP. These themes and their 
corresponding codes are represented in a thematic map 
(Figure 1). While all of the themes will be discussed in this 
paper, please refer to Table 2 for examples of quotes for 
each code.  
Perceived confidence and discordant counseling practices 
All participants across the five focus group discussions gave 
a percentage above 80% for whether they counseled on a 
new prescription. The participants’ percentages increased 
to 90% or greater when discussing prescription opioids. 
When asked to rate their comfort level with counseling, 
pharmacists expressed high levels of comfort with 
counseling on both new and opioid prescriptions. However, 
further discussion revealed a discordance between their 
confidence in their ability to counsel patients and their 
actual practices. For example, when faced with the difficult 
situation of denying a prescription to a patient, participants 
varied in how they would handle it. Some indicated that 
they would claim that they were out of stock rather than 
explain why they were refusing to fill, and others said that 
they would have no problem telling the patient why. 
“I don't fret about it. I say, ‘it says that you got 
some filled at this-and-this pharmacy at this date, 
so you should have plenty and I'm not filling this 
prescription.’” (Focus Group 1) 
Throughout the rest of the discussion, participants 
attributed the discrepancies between self-reported 
confidence and practice to structural factors and the 
inadequacy of the infrastructure around them. It also 
became evident that some degree of the disconnect could 
be accounted for by individual factors.  
Inadequate infrastructure 
When discussing new prescriptions, the most common 
barriers to providing counseling were time constraints, 
patient refusal of counseling, and language barriers. 
“If I'm on the phone and they don't want to wait, 
or they don't wait for me to go up to the register 
and talk to them.” (Focus group 1) 
Table 1. Focus group participant demographic information (n=45) 
    Group 1 Group 2 Group 3 Group 4 Group 5 Total 
Number of participants 7 10 9 11 8 45 
Sex       
Male 1 5 5 3 2 16 
Female 6 5 4 8 6 29 
Current Employer Type       
Chain 3 3 5 6 5 22 
Independent 4 7 4 5 3 23 
Years of Experience       
Less than 10 years 1 0 1 1 3 6 
11-20 years 3 3 4 4 3 17 
Greater than 20 years 3 7 4 6 2 22 
Note: Focus groups were conducted in May 2018          
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“I had a patient who told me, ‘I know how to read, 
I don't need you.’” (Focus Group 3) 
“This is probably specific to my store. I have a 
large Hispanic population. I do speak Spanish, but 
I think some people in the Hispanic population 
don't understand the concept of actually being 
counseled. So, they walk off.” (Focus Group 1) 
For opioid prescriptions specifically, respondents indicated 
those same barriers, but also extrapolated on some others. 
These include the patient perceiving the pharmacist as 
accusing them of misuse and the pharmacists’ fear for their 
own safety. 
“And the other thing is how the patient may 
perceive you counseling them on this particular 
type of medication. They may feel like, "Well, why 
are you talking to me about [the prescription]? 
I'm not an addict.” (Focus Group 3) 
“I don't argue with them. Most of the time, my 
escape mechanism is, ‘I don't have it.’ Because I 
don’t want to have a confrontation. I don’t want 
you to wait for me after work. I've got two kids 
I'm going home to.” (Focus Group 2) 
Lastly, participants also expressed that much of the burden 
of verifying misuse and limiting inappropriate misuse had 
been left to them, thereby misaligning their role.  
Lack of comprehensive counseling 
The focus group discussions also revolved around a series 
of questions regarding the pharmacists’ practices when 
counseling on either a new prescription or an opioid 
prescription. Initially, the moderator did not specify any 
examples so as to not provide any leading questions. 
During this time, there was a general lack of consensus on 
the definition of a new prescription. 
“Somehow when you said new prescriptions, 
some of them said new prescription, but the 
patient has been on it forever. Like some things 
like that, it's not really new.” (Focus Group 2) 
In contrast, the overemphasis of clinical factors was almost 
unanimous. Participants elaborated on the side effects, the 
indication, and the patient’s level of familiarity with the 
medication. In the case of opioid prescriptions, 
respondents expressed a strong awareness for the ongoing 
opioid crisis, therefore, the potential for dependency and 
misuse associated with these medications. 
“I explain the use, because some drugs have 
several uses. The most important thing [is] are 
they allergic [or have had] any allergy reaction. I 
explain to them the possible side effects.” (Focus 
Group 3) 
“Contraindications I feel they need to know 
about, that kind of thing, and then I'll ask them if 
Figure 1. Map of themes and corresponding codes emerged from thematic analysis 
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they have any questions, once I've done my legal 
part.” (Focus Group 2) 
“I will start with telling them the duration that the 
doctor told them to take it, and I'll tell them that, 
‘This is if you need it. You don't have to feel 
mandatory to take it, because if you don't [need 
it] you shouldn't take it.’” (Focus Group 2) 
A few participants mentioned proper storage and disposal 
of the medication unprompted, and when this occurred, 
the moderator encouraged the group to elaborate further 
on the topic. However, the majority of respondents 
neglected to bring up storage and disposal as part of their 
medication counseling. When this occurred, the moderator 
specifically asked about these topics. This part of the 
discussion yielded more inconsistencies in individual 
awareness.   
“You can't talk about disposal if there's no place 
to dispose of it. Some states have them, Texas 
does not. Not yet, and it says pharmacies can't be-
I mean, just imagine if I told everybody, ‘Bring me 
your Vicodins that you don't want to take.’ I'd get 
broken into that night.” (Focus Group 2) 
In the context of prescription opioids, discussion of 
counseling on storage included the potential for diversion 







High Confidence in Ability to 
Counsel 
“I do 100% on all the opioids because of the drowsiness possibility.” (Focus group 4) 
Aversion to Training 
“We already know that stuff. All that stuff that you just said, we already know or have 
incorporated into our day already. So to go and take a class on that, unless you're going 
to pay $250 like now, that's another story. I'll go to that class.” (Focus group 2) 
Refusal to Fill Actions 
“I don't fret about it. I say it says that you got some filled at this-and-this pharmacy at 




Overemphasis of Clinical 
Factors 
“Contraindications I feel they need to know about, that kind of thing, and then I'll ask 
them if they have any questions, once I've done my legal part.” (Focus group 2) 
Neglect of Safe 
Storage/Disposal Information 
“You can't talk about disposal if there's no place to dispose of it. Some states have them, 
Texas does not. Not yet, and it says pharmacies can't be-I mean, just imagine if I told 
everybody, ‘Bring me your Vicodins that you don't want to take.’ I'd get broken into that 
night.” (Focus Group 2) 
 
“Now one thing I will discuss with patients [is] do not let any of your friends and family 
know that you are on this medication, because they will steal their medications.” (Focus 
group 1) 
 
“They will break into your house and take it, or they will steal your purse if they know 
you have it.” (Focus Group 4) 
Lack of Awareness of Referral 
Services 
 “Sometimes … I try to find something close by them or get them hooked up with a 
doctor somewhere so they can get treated... We look-thank God for the internet.” (Focus 
group 1) 
 
 “I didn’t do a referral. When I kicked a prescription, I called the doctor[s] and let them 
[doctors] know I'm not filling that prescription and tell him or her how the patient is 
acting.  I leave it up to the doctor after that.” (Focus group 3) 
Variance in Definition of a 
New Prescription 
The patient has been on the medication and does not need to be counseled. (Focus 
group 2) 
Sensitivity to Opioid Crisis 
“They're spending the money. They're just spending it wrongly because I represented my 
institution at [INAUDIBLE] for two straight weeks where we discussed addiction and we 
had pharmacologists there. We had social studies people. We had MDs, we even had 
MDs that were confessing right there as we sat around the bench telling their stories 
about how they got over addiction. So that whole thing was sponsored by the NIH and 
we were there for two weeks. That's really one of the reasons why I said it has to be a 
holistic approach. If you keep dealing with one pocket at a time then there is no- So 





“I don't argue with them. Most of the time, my escape mechanism is, "I don't have it." 
Because I don’t want to have a confrontation. I don’t want you to wait for me after work. 
I've got two kids I'm going home to.” (Focus group 2) 
Time Constraint 
“They don't want to wait after that.” (Focus group 1) 
 
“If I'm on the phone and they don't want to wait, or they don't wait for me to go up to 
the register and talk to them.” (Focus group 1) 
Language Barrier 
“This is probably specific to my store. I have a large Hispanic population. I do speak 
Spanish, but I think some people in the Hispanic population don't understand the 
concept of actually being counseled. So, they walk off.” (Focus group 1) 
 
“In my area, everybody speaks Spanish, but all my technicians speak Spanish and it's 
totally fine. If it's Vietnamese, we have nobody who speaks Vietnamese.” (Focus group 5) 
Infeasible to Engage All 
Patients 
“I had a patient who told me, ‘I know how to read, I don't need you.’” (Focus group 3) 
Misaligned Role of Pharmacist “If they would put the doctors on the front line with us.” (Focus group 1) 
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and the need to prevent others from accessing their CSP. 
 “Now one thing I will discuss with patients [is] do 
not let any of your friends and family know that 
you are on this medication, because they will steal 
their medications.” (Focus Group 1) 
“They will break into your house and take it, or 
they will steal your purse if they know you have 
it.” (Focus Group 4) 
When asked about what pharmacists do when they 
encounter a patient who they suspect of experiencing an 
opioid dependency or at risk for one, participants exhibited 
an overall lack of awareness regarding referral services. As 
a result, they often resort to other methods to get their 
patient the help they need. 
“Sometimes … I try to find something close by 
them or get them hooked up with a doctor 
somewhere so they can get treated... We look-
thank God for the internet.” (Focus Group 1) 
 “I didn’t do a referral. When I kicked a 
prescription, I called the doctor[s] and let them 
[doctors] know I'm not filling that prescription and 
tell him or her how the patient is acting.  I leave it 
up to the doctor after that.” (Focus Group 3) 
Inconsistent use of the PDMP 
When participants were asked what they consider to be 
signs of misuse, the conversation turned to the usage of 
PDMPs. Respondents did confirm the PDMP to be a helpful 
tool in their decision-making process when suspecting 
misuse. However, they also revealed that they were 
inconsistent in which patients they reviewed. Familiarity or 
rapport with the patient was associated with usage of the 
PDMP, as was the level of knowledge a patient had 
regarding their medication, clinical indication, and the 
pharmacy. The PDMP in Texas is called the Prescription 
Monitoring Program (PMP). 
“Well, it would have to-I would have to see-really 
what helps me to make my decision is what I 
looked at and find in PMP. And basically, I had a 
gentleman and I didn't fill his prescription because 
I really thought first of all, there's no way you're 
taking all these, and who in the world is giving 
you-this has got to be a trap from the state 
board.” (Focus Group 2) 
“Well, I have people who get it every month, and 
so I don’t check those, but even if they get regular 
whatever medication and this is the first time they 
brought in an opioid, we check. And if they’ve 
never been there, of course we check.” (Focus 
Group 5) 
Pharmacists’ desired training/assistance  
The final point of discussion for each focus group was their 
preferences for further training. The moderator outlined 
two training components – knowledge on controlled 
substance medications or training on communication skills 
– and asked who would be interested in one or both 
options for training. The participants had mixed responses 
overall. Those that were interested in training were asked 
to further elaborate on what the training should consist of 
and how they would prefer the training to be administered. 
Those that were not interested claimed that outside 
Table 2 (cont.). Focus group discussions themes, corresponding codes, and example quotes 
Inconsistent Use of 
PDMP 
Patients Suspected of Misuse 
“I don't argue with them. Most of the time, my escape mechanism is, ‘I don't have it.’ 
Because I don’t want to have a confrontation. I don’t want you to wait for me after work. 
I've got two kids I'm going home to.” (Focus group 2) 
Familiarity/Rapport 
“I have filled that combination for one patient whose history I know, but they also take a 
whole lot of other medications because they have multiple mental health issues, physical 
issues, and real disease states that are well beyond just like-also their diabetes 
medication. They have a blood-clotting disorder. So I'm just like I know a whole lot about 
this patient and it's not just oh, I'm coming in to just get the cocktail. So but that is really 
rare compared to just the people that come in for just those.” (Focus group 1) 
 
“Well, I have people who get it every month, and so I don’t check those, but even if they 
get regular whatever medication and this is the first time they brought in an opioid, we 
check. And if they’ve never been there, of course we check.” (Focus group 5) 
Patient Knowledge 
“Sometimes you do probing questions, kind of by the feel of what they're there for: 
‘Why are you taking it? Do you know how long you're going to be taking it? Did the doctor 
and you discuss that?’ And then after that, you tell them what they're taking and tell some 
of the cautions of taking it, and especially in combination when they have more than one, 




Support from Other 
Stakeholders 
“The thing is, though, pharmacists are going to need beyond the education - will need the 
support to implement. Because the bottom line is, we could - we're the most accessible 
healthcare professionals. Tell a nurse, too. It's true, because they can find us in locations 
like that. However, we've got a ton of work to do there. So, they're - that may be where 
some of these new jobs need to be created for all the pharmacy [INAUDIBLE] they've 
created. And the pharmacists that are coming out and are running into challenging finding 
work. So, in my mind, it's a number of different trainings. But it's a whole program, 
because if this United States is in the epidemic, and it is an epidemic of drug abuse. Then 
why should we not focus on something like that to make a difference in the lives of people 
in our country.” (Focus group 5) 
On the Job Training 
“The most important thing is what you see on a daily basis. That on the-job training is the 
best kind.” (Focus group 1) 
Advocacy for Patients 
“Narcan so that we have a better understanding that we can counsel and teach the 
patients and caregivers, like you were talking about earlier” (Focus group 5) 
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training would not be beneficial because the only effective 
way for new pharmacists to learn would be to gain 
experience on the job. 
“We already know that stuff. All that stuff that 
you just said, we already know or have 
incorporated into our day already.” (Focus Group 
2) 
The most common training components asked for were 
information on new and existing medications, potential 
signs of misuse, and assistance in communication with 
patients.  
“[Someone] was saying it's obvious when 
someone was abusing, for me it's actually not that 
obvious. I have to use the red flags.” (Focus Group 
1) 
“… I want something that's geared toward me, 
community pharmacy, and – ‘Hey, look. These are 
the common new cocktails. This is what you can 
do for this.’ Because my knowledge on Suboxone 
and Methadone, I'm embarrassed, but it's 
lacking.” (Focus Group 5) 
Participants that did not want training expressed a desire 
for more involvement or changes in practice from other 
health care stakeholders to alleviate the burden on them.  
“I think the other thing is the insurance 
companies. They should require the patients 
themselves, to have [to watch] a video, about 
what they have prescribed for them. It [the video] 
talks about the opioid crisis maybe in general and 
not so much as counseling, it just talks about what 
this medication can actually do if taken in the 
wrong way. Just kind of give them a heads up. So 
when we [pharmacists] do approach them, 
they're more comfortable with [having] the 
conversation with their pharmacist.” (Focus 
Group 3) 
When asked for their preferred modality to receive 
training, participants’ answers varied, with no general 
consensus for any singular training modality. However, 
participants did bring up the helpfulness of a tangible 
resource when counseling.  
“I remember when I was at Walgreens, they did a 
sheet and I read it once, and it was pretty decent. 
It was step by step, [of] what to do, how to 
approach the patient, [and] what to say. It was 
really good. It told you even how to say I'm not 
comfortable filling this prescription. So one sheet 




From this study, the most pervasive theme was the 
discordance between the pharmacists’ self-reported 
confidence in their ability to counsel and the counseling 
practices they exhibited. Participants reported that they 
counseled on 80% or greater of all new prescriptions and 
that they were very comfortable when counseling on them. 
A new prescription in Texas is formally defined as “a 
prescription drug order that has not been dispensed to the 
patient in the same strength and dosage form by this 
pharmacy within the last year”.
12
 In the focus groups, 
participants debated on what they would consider to be a 
new prescription. Some claimed that if the patient had 
never been on the medication before, then it was a new 
prescription. Others stated that if the patient had been on 
the medication previously, but the prescription was 
renewed, then it should be considered a treated as a new 
prescription. Variability in the definition of a new 
prescription could potentially create inconsistencies in 
when pharmacists counsel patients on their medication. 
For example, a participant that states that they counsel on 
80% of new prescriptions may seem as if they are 
counseling consistently as face value. However, if their 
definition of a new prescription is much narrower than the 
legal definition, they may not be counseling as frequently 
as they’re expected to.  
In the case of counseling a patient with an opioid 
prescription, participants reported even higher percentages 
(>90%) for when they counsel, and that they were equally 
or more comfortable counseling on an opioid prescription 
as they were with any new prescription. However, further 
discussion elicited beliefs contradictory to comfort with 
patients filling an opioid medication. When discussing 
barriers to counseling, participants cited structural issues 
such as time constraints, language barriers, and in the 
context of opioids, pharmacist safety. The last concern led 
to some pharmacists feeling that “If they're abusing, I don't 
want them to come back” (Focus Group 4). Their fears were 
not completely unfounded, since many of the participants 
knew pharmacists who had faced potentially threatening 
situations when interacting with a patient filling a CSP. 
Negative behavioral beliefs among pharmacists towards 
engaging patients suspected of misusing CSPs has been 
well-documented.
20
 It is also important to note that 
patients with OUD have expressed fear of judgement or 
retaliation while they attempt to seek treatment or 
recovery options through community pharmacies.
23
 The 
participants in the focus group discussions also mentioned 
their hesitance to pull aside a patient with an opioid 
prescription for counseling for fear of being perceived as 
accusatory.  
When asked what could be done to alleviate this burden on 
them, many of them cited more involvement from other 
health care stakeholders. One participant suggested that 
the situation would improve, “If they would put the doctors 
on the front line with us” (Focus group 1). The factors 
mentioned above could be attributed to a general lack of 
sufficient structural and organizational support, thereby 
hindering pharmacists from fulfilling their roles as 
advocates for the health of the communities they serve. 
However, it is also important to recognize that even if these 
hindrances were addressed, there are still individual-level 
factors that prevent pharmacists from delivering 
comprehensive counseling.  
When the moderator asked what the participants 
counseled on once they decide to do so, participants 
exhibited an overemphasis on the clinical factors. Very few 
participants brought up storage and disposal on their own. 
According to the TSBP, counseling a patient on a 
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medication should include safe usage, storage, and disposal 
of the medication.
12
 If the medication is a controlled 
substance, then the pharmacist should also discuss the 
potential for diversion, the risk for misuse, and potential 
referral services the patient could go to for more 
information or help.
12
 Time constraints have been cited as 
the most common control belief preventing them from 
counseling, and could be the primary reason why 
pharmacists are unable to cover all of the components of 
counseling with each patient.
20
 However, it is also possible 
that pharmacists may not have a clear knowledge base 
regarding what options are available to discuss with 
patients. This possibility came to light when discussing safe 
disposal and referral options. As seen in the results, the 
moderator asked the participants if they were aware of 
drug deactivation devices, such as Deterra® or DisposeRx®. 
Most participants in the focus groups were unaware of 
them, in line with previous research.
24
 
Another individual-level factor that lead to a lack of 
comprehensive counseling was the inconsistency with 
which the pharmacists used the PDMP. PDMPs are state-
maintained electronic databases that track controlled 
prescription medication fill history. They can be important 
tools when looking for signs of misuse, but their potential is 
squandered when not used consistently, or if the reasoning 
behind reviewing patients is arbitrary.  
Familiarity and rapport with the patient can be beneficial 
when a patient is suffering from OUD and the pharmacist 
feels comfortable enough to have a conversation with that 
patient. However, this relationship seems to hinder the 
pharmacist’s judgment when it comes to reviewing them in 
the PDMP. One pharmacist claimed that they would not 
check the PDMP for a patient they see on a regular basis. 
On the other hand, a lack of familiarity and rapport with a 
patient seems to encourage pharmacists to ask more 
questions from the patient. At the surface level, this seems 
to be a better practice than being lenient on patients they 
are familiar with; however, this may also be a detrimental 
practice. While patient knowledge of their disease state 
was an indicator of legitimate use for some pharmacists, 
other pharmacists indicated that a patient that knew too 
much about the medication was probably misusing. 
Familiarity or rapport with the patient seems to reduce 
stigma for patients attempting to receive treatment, but it 
should not be the primary consideration in a pharmacist’s 
decision to dispense a medication.  
Pharmacists also described that they feel as if they’ve been 
on the “front lines” of the opioid epidemic. There is merit 
to this assertion since pharmacists are responsible for 
deciding whether to fill and dispense any prescription.
23,25
 
While physicians often have the hospital, nurses, and other 
physicians working in close proximity to them, community 
pharmacists are more isolated. Even those who use the 
PDMP don’t always have the same information that the 
prescribing physician does (e.g., diagnosis, source of pain). 
In this situation, the pharmacist can contact that physician, 
but this approach has mixed results, due to difficulty 
getting in contact with the prescriber.  
In the final part of the focus group discussions, participants 
were asked what kind of training they would benefit from. 
Respondents outlined a need for involvement from other 
health care stakeholders. They specifically named insurance 
companies, physicians, and their employers as entities that 
need to be more involved in efforts to ameliorate the 
opioid crisis. Improved communication between 
pharmacists and other stakeholders can alleviate the 
burden on pharmacists. The disconnect between 
pharmacists and physicians cause pharmacists to make 
decisions about the patient care while lacking important 
health information.
27
 Access to the PDMP has reduced this 
issue, but in order to resolve it, there needs to be a better 
flow of information between the pharmacist and physician.  
One possible solution to this is to consider the idea of 
increased Electronic Health Record (EHR) interoperability to 
include PDMP databases, so that pharmacists have access 
to the same clinical information that physicians are privy to. 
More importantly, this integration would also lessen the 
chasm between physicians and pharmacists and unite them 
in their efforts to address the opioid epidemic. 
In concordance with previous studies, community 
pharmacists feel that the TSBP and the supervisors directly 
overseeing them have a great deal of influence over their 
daily practices within the pharmacy.
29
 Given this, offering 
training as a requirement from the TSBP or their employer 
may be the best way to ensure all pharmacists are trained 
properly on how to counsel on controlled substance 
prescriptions. Another possible setting for intervention, 
especially with student pharmacists, would be to 
implement change to the curriculum for the gaps identified. 
To comply with the opinion that on the job training would 
be the most effective modality, the training should consist 
of a series of simulations. These simulations should 
emulate real-world situations that pharmacists could face.  
Limitations 
Participation in this study was limited to community 
pharmacists in a large metropolitan area in the southern 
United States, which may introduce selection bias. The 
majority of participants in this study self-reported 10+ 
years of experience, so it is possible that some of the 
pharmacy practice information shared by these participants 
may not align with the current best practice 
recommendations. Limited demographic information was 
collected, which may limit the ability to interpret findings. 
Furthermore, participants in this study were not asked to 
recall information over a certain period of time, so this can 
lead to recall bias due to participants not remembering 
accurately or omitting details. Lastly, some participants in 
this study proved to be more vocal and willing to share 
their opinions, so social desirability may have suppressed 
some opposing viewpoints. 
 
CONCLUSIONS 
This study furthers our understanding of the pharmacist-
patient interaction, thereby allowing us to identify gaps in 
current practices. To improve this relationship, training 
interventions need to be designed to allow for more 
comprehensive counseling on prescription medications. 
The training interventions should be geared towards 
offering services that address language barriers, training 
pharmacists on how to more effectively engage patients in 
need of counseling and increasing pharmacy support staff 
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in order to increase the availability of the pharmacist to 
patients. 
While this study has provided valuable insight into an 
ongoing issue, there is still further need for research in key 
areas: (1) identifying the most effective forms of 
educational interventions to address the overall lack of 
awareness pharmacists exhibited in comprehensive 
counseling practices; (2) specific gaps in communication 
between the pharmacist and prescriber need to be 
identified and a better mode of information transfer needs 
to be designed, potentially through EHR interoperability. 
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